Understanding Van Gogh's Night: bipolar disorder

Vincent Van Gogh (1853-1890) imparted in his art a deep essence of life, and in such a unique way that many would say it is possible to experience it vicariously by looking at his paintings even once. In 10 years, while exerting mental and physical efforts that may well have contributed to his premature death, he produced an impressive number of masterpieces. However, the specific neurological disorder Van Gogh suffered and how this may have influenced his art is still not clear. The combination of his eccentric personality, irascible temper, unstable moods and prolific creativity, makes the understanding of his illness a very complex endeavor and therefore poses a great challenge to those who investigate the relationships between the 'artistic mind', the brain and illness. In fact, most of the diagnoses (nearly 30) proposed for Van Gogh, during the last century, are not based on medical evidence but are ascertainable from analyses of his paintings and biographical data. Although no definitive diagnosis can be made based on such evidence, we conclude that according to DSM-IV criteria and findings extrapolated from his letters, Van Gogh is most likely to have suffered a bipolar disorder, affective or schizoaffective, which caused his death by suicide.

[Illustrations de Oeuvres] / Chéron, dess. ; Vertue, dess. Van der Gucht, C. du Bosc et P. Fourdrinier, grav. ; Jean Racine, aut. du texte

Comprend : [Tome I. Bandeau à la Dédicace : lion et licorne entourant les armoiries et la devise du Duc de Glocester.] Honi soit qui mal y pense. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome I. Pl. en reg. folio B : la Thébaïde ou les frères ennemis. Tragédie.] Thébaïde. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome I. Pl. en reg. du titre de la tragédie Alexandre le grand :] Alexandre. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome I. Pl. en reg. du titre de la tragédie Andromaque :] Andromaque. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome I. Pl. en reg. du titre de la tragédie Britannicus :] Britannicus. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome I. Pl. en reg. du titre de la tragédie Berenice :] Berenice. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome I. Pl. en reg. du titre de la comédie Les Plaideurs :] Les Plaideurs. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome II. Frontispice :] [Cote : Yf 404-405/Microfilm R 122414] ; [Tome II. Pl. en reg. du titre de la tragédie Bajazet :] Bajazet. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome II. Pl. en reg. du titre de la tragédie Mithridate :] Mithridate. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome II. Pl. en reg. du titre de la tragédie Iphigénie :] Iphigénie. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome II. Pl. en reg. du titre de la tragédie Phèdre :] Phèdre. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome II. Pl. en reg. du titre de la tragédie Esther :] Esther. [Cote : Yf 404-405/Microfilm R 122414] ; [Tome II. Pl. en reg. du titre de la tragédie Athalie :] Athalie. [Cote : Yf 404-405/Microfilm R 122414]

90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial.

PURPOSE Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. PATIENTS AND METHODS Patients with CD20(+) stage III or IV FL with complete response (CR), unconfirmed CR (CRu), or partial response (PR) after first-line induction treatment were randomly assigned to (90)Y-ibritumomab consolidation therapy (rituximab 250 mg/m(2) days -7 and 0, then (90)Y-ibritumomab 14.8 MBq/kg day 0; maximum 1,184 MBq) or no further treatment (control). Primary end point was progression-free survival (PFS) from date of random assignment. Results For 409 patients available for analysis ((90)Y-ibritumomab, n = 207; control, n = 202), estimated 8-year overall PFS was 41% with (90)Y-ibritumomab versus 22% for control (hazard ratio [HR], 0.47; P < .001). For patients in CR/CRu after induction, 8-year PFS with (90)Y-ibritumomab was 48% versus 32% for control (HR, 0.61; P = .008), and for PR patients, it was 33% versus 10% (HR, 0.38; P < .001). For (90)Y-ibritumomab consolidation, median PFS was 4.1 years (v 1.1 years for control; P < .001). Median time to next treatment (TTNT) was 8.1 years for (90)Y-ibritumomab versus 3.0 years for control (P < .001) with approximately 80% response rates to second-line therapy in either arm, including autologous stem-cell transplantation. No unexpected toxicities emerged during long-term follow-up. Estimated between-group 8-year overall survival rates were similar. Annualized incidence rate of myelodysplastic syndrome/acute myeloblastic leukemia was 0.50% versus 0.07% in (90)Y-ibritumomab and control groups, respectively (P = .042). CONCLUSION (90)Y-ibritumomab consolidation after achieving PR or CR/CRu to induction confers 3-year benefit in median PFS with durable 19% PFS advantage at 8 years and improves TTNT by 5.1 years for patients with advanced FL.

Euroopan yhteisöjen tuomioistuimen tuomio 17.11.1998 asiassa C-391/95 (Van Uden) : Brysselin yleissopimus - välityslauseke - ennakkona maksettava maksu - väliaikaisten toimenpiteiden käsite

Ratkaisu koskee Brysselin yleissopimuksen 24 artiklaan perustuvaa tuomioistuimen toimivaltaa turvaamistoimiasiassa